NewAmsterdam Pharma Company NV has published a document on the safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH). The document details patient demographics, baseline lipoprotein lipids, and the significant reductions in LDL-C levels observed with obicetrapib treatment compared to placebo. It also covers changes in other lipid parameters and highlights that obicetrapib was well-tolerated with no serious adverse events. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.